Literature DB >> 18285481

Anti-BK virus activity of nucleoside analogs.

Parmjeet Randhawa1, Jiri Zemlicka, Andreas Sauerbrei, Chris Meier, Karl Y Hostetler, James R Beadle, Noush Afarin Farasati, Yuchen Huang, Matthews Bradley.   

Abstract

Polyomavirus BK is an important pathogen in transplant recipients with no effective therapy. This study demonstrates that alkoxyalkyl esters of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and fatty acid derivatives of 9-[2-(phosphonomethyoxy)ethyl]adenine (P393 and P405) are potent and selective inhibitors of BK virus replication in vitro, with a 50% effective concentration in the micromolar-to-nanomolar range.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18285481      PMCID： PMC2292553          DOI： 10.1128/AAC.01241-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.

Authors:  C Meier; T Knispel; E De Clercq; J Balzarini
Journal:  J Med Chem       Date:  1999-05-06       Impact factor: 7.446

2.  CycloSal-BVDUMP pronucleotides: how to convert an antiviral-inactive nucleoside analogue into a bioactive compound against EBV.

Authors:  Chris Meier; Andreas Lomp; Astrid Meerbach; Peter Wutzler
Journal:  J Med Chem       Date:  2002-11-07       Impact factor: 7.446

3.  Inhibitory activity of 3'-fluoro-2' deoxythymidine and related nucleoside analogues against adenoviruses in vitro.

Authors:  R Mentel; M Kinder; U Wegner; M von Janta-Lipinski; E Matthes
Journal:  Antiviral Res       Date:  1997-05       Impact factor: 5.970

4.  Activities of various compounds against murine and primate polyomaviruses.

Authors:  G Andrei; R Snoeck; M Vandeputte; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6.

Authors:  D Reymen; L Naesens; J Balzarini; A Holý; H Dvoráková; E De Clercq
Journal:  Antiviral Res       Date:  1995-12       Impact factor: 5.970

6.  Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides.

Authors:  Shaoman Zhou; Julie M Breitenbach; Katherine Z Borysko; John C Drach; Earl R Kern; Elizabeth Gullen; Yung-Chi Cheng; Jiri Zemlicka
Journal:  J Med Chem       Date:  2004-01-29       Impact factor: 7.446

7.  Chemistry and anti-herpes simplex virus type 1 evaluation of cycloSal-nucleotides of acyclic nucleoside analogues.

Authors:  C Meier; L Habel; F Haller-Meier; A Lomp; M Herderich; R Klöcking; A Meerbach; P Wutzler
Journal:  Antivir Chem Chemother       Date:  1998-09

8.  Quantitation of viral DNA in renal allograft tissue from patients with BK virus nephropathy.

Authors:  Parmjeet S Randhawa; Abhay Vats; Deborah Zygmunt; Patricia Swalsky; Velma Scantlebury; Ron Shapiro; Sydney Finkelstein
Journal:  Transplantation       Date:  2002-08-27       Impact factor: 4.939

9.  Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus.

Authors:  D F Smee; B B Barnett; R W Sidwell; E J Reist; A Holy
Journal:  Antiviral Res       Date:  1995-01       Impact factor: 5.970

10.  Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.

Authors:  Robert O Baker; Mike Bray; John W Huggins
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 10.103
View more
  5 in total

1.  Molecular characterization of BK virus in patients infected with human immunodeficiency virus.

Authors:  Danijela Karalic; Ivana Lazarevic; Ana Banko; Maja Cupic; Djordje Jevtovic; Tanja Jovanovic
Journal:  Med Microbiol Immunol       Date:  2015-10-26       Impact factor: 3.402

2.  BK virus infection in human immunodeficiency virus-infected patients.

Authors:  J Ledesma; P Muñoz; D Garcia de Viedma; I Cabrero; B Loeches; P Montilla; P Gijon; B Rodriguez-Sanchez; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-16       Impact factor: 3.267

3.  Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication.

Authors:  Parmjeet S Randhawa; Noush A Farasati; Yuchen Huang; Markus Y Mapara; Ron Shapiro
Journal:  Am J Clin Pathol       Date:  2010-12       Impact factor: 2.493

4.  Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

Authors:  Karl Y Hostetler
Journal:  Antiviral Res       Date:  2009-05       Impact factor: 5.970

5.  A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Francisco M Marty; Drew J Winston; Roy F Chemaly; Kathleen M Mullane; Tsiporah B Shore; Genovefa A Papanicolaou; Greg Chittick; Thomas M Brundage; Chad Wilson; Marion E Morrison; Scott A Foster; W Garrett Nichols; Michael J Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-04       Impact factor: 5.742
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.